Tigecycline
Tigecycline.JPG

CLINICAL USE

Antibacterial agent

DOSE IN NORMAL RENAL FUNCTION

Loading dose of 100 mg, then 50 mg twice daily

PHARMACOKINETICS

  • Molecular weight                           : 585.6
  • %Protein binding                           : 71–89
  • %Excreted unchanged in urine     : 22
  • Volume of distribution (L/kg)       : 7–9
  • half-life – normal/ESRD (hrs)      : 42/Probably unchanged

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : Dose as in normal renal function
  • 10 to 20     : Dose as in normal renal function
  • <10           : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                : Not dialysed. Dose as in normal renal function
  • HD                     : Not dialysed. Dose as in normal renal function
  • HDF/high flux   : Unknown dialysability. Dose as in normal renal function
  • CAV/VVHD      : Unknown dialysability. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs
  • Anticoagulants: possibly enhanced anticoagulant effect of coumarins
  • Oestrogens: possibly reduced contraceptive effects of oestrogens (risk probably small)

    ADMINISTRATION

    Reconstition

    5.3 mL of sodium chloride 0.9% or glucose 5% (gently swirl to reconstitute)

    Route

    IV infusion

    Rate of Administration

    30–60 minutes

    Comments

    Add required dose to 100 mL of sodium chloride 0.9% or glucose 5%

    OTHER INFORMATION

    AUC increased by 30% in CKD 5 .



    See how to identify renal failure stages according to GFR calculation

    See how to diagnose irreversible renal disease

    Home

  • other drugs